TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Stefan S Bielack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.